|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, we identify a subset of melanoma cells producing IL-15, possibly involved in tumor escape mechanisms.
|
9627116 |
1998 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To test whether the p53-impaired function that is frequently found in this tumour type could play a role in the IL-15 production, wild-type p53 gene was transduced in the human rhabdomyosarcoma cell line RD (which harbours a mutated p53 gene), and its effect on proliferation and expression of IL-15 was studied.
|
9862562 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, tumor therapy based on IL-15 gene transfection was effective against Meth A tumor cells, suggesting a possible application to human neoplasms.
|
10359107 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumour cells engineered to secrete interleukin-15 augment anti-tumour immune responses in vivo.
|
10424745 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma.
|
10627470 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
N592 cells engineered with IL-2 (N592/IL-2) were promptly rejected, while N592/IL-15 displayed a significant delay in tumour growth and a slightly reduced take rate.
|
10861581 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Stimulation of DC for 24 hours with CD40 ligand (CD154), IL-12 or IL-15 prior to their co-incubation with prostate cancer cells resulted in a significant increase in DC survival in the tumour microenvironment.
|
10945499 |
2000 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Considering the significant overexpression of IL-15 and IL-16 and their biological capacities it is likely that these cytokines contribute to the tumor development.
|
10949545 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, macrophages cocultured with N592/IL-12/IL-15 produced NO in vitro, and inhibited tumor cell growth, further suggesting their role as effector cells in this model.
|
10975824 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have demonstrated elevated expression levels of NF-kappa B--inducible cytokines, including interleukin (IL)-6, IL-10, IL-15, and interferon (IFN)-gamma, in freshly isolated primary tumors from Tax transgenic mice.
|
11493471 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transcripts for IL-2 family cytokine (IL-2, IL-7, IL-9, IL-15) and receptors (IL-2Ralpha, IL-2Rbeta, gammac, IL-7Ralpha, IL-9Ralpha, IL15Ralpha) and IL-12 family cytokine (IL-12p40) and receptors (IL-12Rbeta1 and IL-12beta2) were essentially absent in both tumors and cell lines.
|
11810184 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The human MHC class I-negative small cell lung cancer cell line, N592, genetically engineered to secrete IL-15, N592/IL-15, showed a reduced tumor growth rate, while N592 cells engineered with IL-12, N592/IL-12, grew similarly to the wild-type N592, N592 parental cells (N592pc), in nude mice.
|
12847220 |
2003 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The combined treatment with B78/IL-12 cells and IL-15 activated not only a local response against tumour, but also induced systemic antitumour immunity that led to a delay or inhibition of tumour development at a distant site.
|
14605763 |
2004 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Formation of NO could be the signalling event associated with the activation of apoptosis in muscle of tumour-bearing rats; indeed, administration of IL-15 decreased the inducible nitric oxide synthase protein levels by 73%, suggesting that NO formation and muscle apoptosis during tumour growth are related.
|
15225634 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-15 was found to strongly enhance the immune response directed against ULBP-expressing tumors.
|
16621962 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Juxtacrine function of interleukin-15/interleukin-15 receptor system in tumour derived human B-cell lines.
|
17100778 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, a preassociation with IL-15Ralpha-IgG1-Fc enhances the activities of IL-15 in vivo and in vitro that may be useful in the treatment of tumors.
|
18250415 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
|
18760876 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Effects of immunotherapy of IL-6 and IL-15 plasmids on transmissible venereal tumor in beagles.
|
19200609 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In parallel, IL-7 and IL-15 mRNA, crucial cytokines involved in thymocytes development and cellular homeostasis, respectively, are also down-regulated in the thymuses of tumor hosts as compared to those of normal mice.
|
19421751 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice.
|
19422685 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that compared with CAR.19(+) T cells, iC9/CAR.19/IL-15(+) T cells had: (1) greater numeric expansion upon antigen stimulation (10-fold greater expansion in vitro, and 3- to 15-fold greater expansion in vivo) and reduced cell death rate (Annexin-V(+)/7-AAD(+) cells 10+/-6% for iC9/CAR.19/IL-15(+) T cells and 32+/-19% for CAR.19(+) T cells); (2) reduced expression of the programmed death 1 (PD-1) receptor upon antigen stimulation (PD-1(+) cells <15% for iC9/CAR.19/IL-15(+) T cells versus >40% for CAR.19(+) T cells); and (3) improved antitumor effects in vivo (from 4.7- to 5.4-fold reduced tumor growth).
|
20428207 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, we show that IL-15 transfection induced a selective expansion of antigen-specific CD4(+) T cells ex vivo and enhanced their tumor-suppression effects in vivo.
|
21822803 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IL-15 expressed by transfected tumor cells stimulated spleen cell proliferation in vitro.
|
21956355 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thus, boosting IL-15 activity could enhance innate and specific immunity and fight tumors.
|
22032984 |
2012 |